华海药业(600521.SH)子公司HB0025注射液启动III期临床试验

Core Viewpoint - Huahai Pharmaceutical (600521.SH) announced the initiation of Phase III clinical trials for HB0025, an innovative dual-specificity fusion protein targeting PD-L1 and VEGF for the treatment of squamous and non-squamous non-small cell lung cancer [1] Group 1 - The subsidiary Shanghai Huatai Biopharmaceutical Co., Ltd. will officially start the Phase III clinical trial for HB0025 after discussions with the National Medical Products Administration's Center for Drug Evaluation (CDE) [1] - HB0025 is designed to target both tumor immune evasion pathways (PD-L1) and tumor angiogenesis pathways (VEGF), providing a dual mechanism of action for anti-tumor effects [1] - The drug achieves high-affinity binding to both targets, which helps in the coordinated regulation of the tumor immune microenvironment and angiogenesis [1]